Allison Betof Warner, MD, Stanford Cancer Center, Stanford, CA, shares results from a pilot trial (NCT05640193) that demonstrated the feasibility of lifileucel for active melanoma brain metastases (MBM). All patients successfully completed the trial without presenting complications like seizures or intracranial hemorrhage, and the safety of the modified treatment regimen resembled the standard lifileucel regimen. A majority of patients who underwent surgical excision successfully received the lifileucel infusion. Dr Warner concludes that although the pilot trial showed promising results, further expansion of this trial with careful selection of patients is necessary to ensure the complete safety and efficacy of lifileucel. This interview took place at the Society for Melanoma Research (SMR) 2024 Annual Meeting in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.